Date | Title | Description | |
---|---|---|---|
02 Mar 2021 | On business and financial situation | The Company releases a presentation related to an update of the regulatory processes of its long-acting injectable antipsychotic, Doria®, both in Europe and the United States | Download |
24 Feb 2021 | About corporate governance | The Company informs about the agreements adopted by the Board of Directors | Download |
27 Nov 2020 | On business and financial situation | The Company publishes the results of the PRISMA-3 study of the efficacy and safety of Doria® in schizophrenic patients in the journal npj Schizophrenia | Download |
09 Jul 2020 | On business and financial situation | ROVI informs on the Collaboration with Moderna for Outside the United States Fill-Finish Manufacturing of Moderna’s COVID-19 Vaccine Candidate | Download |
Pages
Date | Title | Description | |
---|---|---|---|
03 Oct 2022 | Liquidity and counterparty agreements | Liquidity contract: transactions conducted in the third quarter of 2022 | Download |
29 Jul 2022 | Other relevant información | On 26 July 2022 the public deed relating to the Company’s share capital decrease was registered with the Commercial Registry of Madrid. | Download |
27 Jul 2022 | On business and financial situation | The Company releases the press release related to the first half 2022 financial results | Download |
27 Jul 2022 | On business and financial situation | The Company releases the first half 2022 financial results presentation | Download |
04 Jul 2022 | Liquidity and counterparty agreements | Liquidity contract: transactions conducted in the second quarter of 2022 | Download |
Pages
Date | Title | Description | |
---|---|---|---|
09 Oct 2015 | Otros sobre operaciones corporativas | Download | |
08 Oct 2015 | Otros sobre operaciones corporativas | Download | |
30 Jul 2015 | Información sobre resultados (2) | Download | |
30 Jul 2015 | Información sobre resultados | Download | |
30 Jun 2015 | Información sobre dividendos | Download |